|
CEP57 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.9960036108132E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.04334335510248E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
9.99200722162641E-16 |
| Stage1-vs-Stage2 |
5.572600E-01 |
| Stage1-vs-Stage3 |
4.344500E-02 |
| Stage1-vs-Stage4 |
6.683500E-02 |
| Stage2-vs-Stage3 |
4.131400E-01 |
| Stage2-vs-Stage4 |
3.201800E-01 |
| Stage3-vs-Stage4 |
8.123400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.66453525910038E-15 |
| Normal-vs-AfricanAmerican |
1.19740000026347E-07 |
| Normal-vs-Asian |
1.84590120966277E-11 |
| Caucasian-vs-AfricanAmerican |
4.369800E-01 |
| Caucasian-vs-Asian |
2.711000E-01 |
| AfricanAmerican-vs-Asian |
9.723000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.77555756156289E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.250200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.6399329650958E-14 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
2.14729999999941E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.494000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.196440E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.667000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.520200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.694200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.686000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.205900E-02 |
| Classical-VS-Follicular |
2.069200E-01 |
| Classical-VS-Other |
9.038600E-01 |
| Classical-VS-Normal |
1.04638520070921E-12 |
| Tall-VS-Follicular |
1.916420E-01 |
| Tall-VS-Other |
2.922200E-01 |
| Tall-VS-Normal |
1.58761892521397E-14 |
| Follicular-VS-Other |
7.684000E-01 |
| Follicular-VS-Normal |
1.63080660087189E-12 |
| Other-VS-Normal |
1.277790E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.76445533131664E-14 |
| N0-vs-N1 |
4.949800E-01 |
|
|
